Scintomics is a leading brand that specializes in innovative tracer technologies for molecular imaging and radioligand therapy in oncology. They are dedicated to targeted diagnostics and therapeutics, also known as theranostics, and the corresponding radiopharmaceutical technologies. With a strong focus on personalized cancer care, Scintomics offers an exceptional portfolio of innovative tracer technologies and actively engages in the clinical development of theranostics through subsidiaries, joint ventures, alliances, and licenses.

Since its establishment in 2006, Scintomics has been committed to developing user-friendly synthesis modules for radiopharmaceuticals and making them available to nuclear medicine clinics and research facilities worldwide. By installing hundreds of synthesis modules, they have built a robust medical and scientific network while consistently delivering on their promise of delivering the best possible outcomes. As one of the leading suppliers of automated synthesizers for theranostics, Scintomics recognized the need for bridging the innovation gap in clinical development.

In 2010, Scintomics expanded its activities to include the promotion of targeted radiopharmaceuticals in the field of oncology. They offer solutions for in-house production of tracers such as PSMA I&T, HA-DOTATATE, Avebetrin, Pentixafor, and other proprietary radiopharmaceuticals like rhPSMA, siPSMA, PSMA. With their rich and unique portfolio, Scintomics is at the forefront of advancing cancer treatment through radio-theranostics.

Visit their website to learn more about how their technologies can improve cancer treatment